|Bid||542.35 x 1800|
|Ask||543.17 x 800|
|Day's Range||533.23 - 556.00|
|52 Week Range||307.44 - 664.64|
|Beta (5Y Monthly)||0.50|
|PE Ratio (TTM)||20.86|
|Earnings Date||Nov 05, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||675.58|
New, daily, U.S. coronavirus cases hit 80,000 on Thursday, with Regeneron posting positive results from its antibody cocktail trial, Moderna saying it is ‘actively preparing’ for a global launch of it vaccine, and Gilead announcing it sold $873 million dollars worth of its antiviral treatment. Yahoo Finance’s Anjalee Khemlani joins The Final Round to discuss the latest on the coronavirus.
Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports third-quarter 2020 results.
Shares of Regeneron Pharmaceuticals Inc. slumped 1.2% in morning trading Friday, after the biotechnology company said an independent data monitoring committee (IDMC) for the REGN-COV2 antibody cocktail treatment trials for COVID-19 recommended that the patient trial be "modified," with the enrollment of some patients place on hold. REGN-COV2 was one of the treatments prescribed to President Trump after he tested positive for COVID-19. Based on a "potential safety signal and an unfavorable risk/benefit profile at this time," the IDMC recommended that further enrollment of patients requiring high-flow oxygen or mechanical ventilation be placed on hold pending analysis of further data. The IDMC also recommends continuing enrollment of patients requiring no or low-flow oxygen and the continuation of the outpatient trial without modification. REGN-COV2 is currently being evaluated by the Food and Drug Administration for a potential Emergency Use Authorization in mild-to-moderate outpatients with high risk of poor outcomes. The stock has lost 13% over the past three months, while the S&P 500 has gained 1.6%.